It functions as a GIP agonist, not antagonist or blocker.
But three injections per week starts to feel burdensome for many people, and the incremental benefit over twice-weekly dosing may not justify the additional injections
Approaches to improvements in efficacy primarily target additional gut hormones via dual- and tri-agonists, and if Mounjaro provides any indication, dual- and tri-agonists may not be likely to enhance tolerability
12 (2021): 59115925, 10.7150/thno.56266
(2022, The Lancet) Study Design: Phase 1b, proof-of-concept, double-blind, placebo-controlled, randomized, multiple-ascending-dose trial in adults with type 2 diabetes
A full medical evaluation is required before starting any treatment